mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern

[1]  S. Perlman,et al.  A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection , 2022, Journal of virology.

[2]  A. Sette,et al.  A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern , 2022, mBio.

[3]  Qian Wang,et al.  Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 , 2022, Nature.

[4]  P. Klenerman,et al.  Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum , 2022, Cell.

[5]  S. Perlman,et al.  RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge , 2022, Translational Research.

[6]  S. Fukushi,et al.  Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants , 2022, Med.

[7]  L. Oostvogels,et al.  A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant , 2022, Vaccines.

[8]  L. Oostvogels,et al.  Third dose of COVID-19 vaccine, CVnCoV, increased neutralizing activity against SARS-CoV-2 wild-type and Delta variant , 2022, medRxiv.

[9]  Fang Li,et al.  Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant , 2022, Cellular & Molecular Immunology.

[10]  K. To,et al.  Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant , 2022, Vaccines.

[11]  Mark M. Davis,et al.  Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses , 2022, Science Translational Medicine.

[12]  Fang Li,et al.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. , 2022, Nanoscale.

[13]  D. Douek,et al.  mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant , 2022, Cell Reports Medicine.

[14]  S. Hubbard,et al.  Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies , 2021, bioRxiv.

[15]  D. Douek,et al.  mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant , 2021, bioRxiv.

[16]  L. Du,et al.  SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies , 2021, Signal Transduction and Targeted Therapy.

[17]  S. Perlman,et al.  COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.

[18]  Shibo Jiang,et al.  Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2 , 2020, Expert opinion on therapeutic targets.

[19]  C. Hillyer,et al.  A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2 , 2020, Cell Research.

[20]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. , 2020, Antiviral research.

[21]  C. Hillyer,et al.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.

[22]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[23]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[24]  Shibo Jiang,et al.  Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses , 2020, Frontiers in Microbiology.

[25]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[26]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[27]  Yufei Wang,et al.  Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.